5-LOX Inhibitors

From Rosacea Support Group: Supplements & Resources
Revision as of 21:43, 9 December 2007 by Dfries2003 (Talk | contribs)

Jump to: navigation, search
Welcome to the

Rosacea Support Resource Pages

These pages hold in-progress web pages for the benefit of Rosacea Support Group members. Information provided herein is intended for informational purposes only and is not intended to replace medical advice offered by a physician or qualified healthcare provider. Feedback welcome to wiki-feedback@rosacea-research.org



Allergen & Pseudo-Allergen

Arachidonic Acid is responsible for the production of a pro-inflammatory series of leukotrienes through the 5-lipoxygenase (5-LOX) pathway, and these leukotrienes along with the prostaglandins and thromboxanes from the cycloxygenase (COX) pathway play a major role in inflammation:

The Role of Leukotrienes in Inflammation

Inhibiting the 5-LOX pathway prevents the production of these pro-inflammatory leukotrienes and seems to help alleviate many of the symptoms associated with inflammation and allergy.

As a warning, since leukotrienes are part of the immune response, inhibiting 5-LOX and the downstream leukotrienes could actually cause a decrease in immune functioning and an increase in parasitic burdens:

Leukotrienes play a role in the control of parasite burden in murine strongyloidiasis.

Inhibition of leukotriene biosynthesis abrogates the host control of Mycobacterium tuberculosis.

Here's a study which suggests this possibility and another discussing the feedback loop that exists between the downstream Leukotriene B4 (LTB4) and the antimicrobial peptide cathelicidin (LL-37):


Leukotriene B4 triggers release of the cathelicidin LL-37 from human neutrophils: novel lipid-peptide interactions in innate immune responses

Of course, there could be other explanations for this, but caution is warranted when using 5-LOX inhibitors, just as caution is warranted with COX inhibitors (including Aspirin).


Some 5-LOX inhibitors are:


Useful links:

http://www.usenet.com/newsgroups/sci.cryonics/msg00081.html